Hannah Clarke

All of those enrolled in the study have been implanted for at least 7 months, with the longest implantation at 15 months.

All patients had prostates greater than 80 mL and had not responded to prior medication therapy.

Dr. Shawn Zimberg and Dr. Dean Laganosky discuss the BioProtect Balloon Transplant System, a rectal spacer for use in prostate cancer radiation.

The median number of harms criteria reported in RCTs in urology increased from 5.3 in 2012 to 7.2 in 2020.

“We found that these genetic proxies of thiazide diuretics were associated with a 15% lower risk of kidney stones,” says Jefferson Triozzi, MD.

"Our studies consistently demonstrated that data from the Decipher Prostate Genomic Classifier was more reliably predictive of prostate cancer progression and underlying pathology than any other clinical data available, including MRI," says Eric Kim, MD.

“The impressive duration of response, still expanding with 6/8 responses ongoing, is indicative of restoration of a lasting immunologic tumor control in advanced solid tumor patients,” says Eugen Leo, MD, PhD, MBA

"In these studies, we were pleased to find that disitamab vedotin has consistent efficacy and manageable safety in patients with chemotherapy-refractory mUC," says Jun Guo, MD.

According to Neuspera, results from phase 2 of the SANS-UUI trial are expected to support an application for FDA approval of the device in patients with OAB-related UUI.

"I'm thrilled to continue my partnership with SMPA to educate and empower others to address their OAB," says Holly Robinson Peete.

The patents apply exclusively to the Ga-68 HBED-PSMA-11 production kit (Locametz), developed by Advance Accelerator Applications.

“The study highlights the importance of considering how altering cell metabolism could impact prostate cancer and its response to treatment," says Jenna Giafaglione.

According to Clarity Pharmaceuticals, the final results are intended to support an application to the FDA for approval of 64Cu-SAR-bisPSMA for imaging in patients with prostate cancer.

Overall, Black men were 24% less likely to receive or be prescribed a novel hormonal therapy agent compared with White men.

Taher Naeem, a fourth-year medical student at Baylor College of Medicine, highlights 3 abstracts that were presented during the 24th Annual Fall Scientific Meeting of the SMSNA in San Diego, California.

The Bladder EpiCheck test received FDA 510(k) clearance in May 2023 for use in patients with NMIBC.

The data showed that Black, Hispanic, and uninsured patients were independently associated with a lower likelihood of receiving immunotherapy.

No dose-limiting toxicities were observed among the initial 3 patients in cohort 3, and no patients experienced adverse events related to 64Cu-SAR-bisPSMA.

The investigators observed no dose limiting toxicities or serious adverse events among all patients who received an ARX517 dose of 3.4 mg/kg, the highest dose tested in the trial.

“[18F]DCFPyL was assessed to be a suitable alternative to [68Ga]Ga-PSMA-11 in PCa diagnosis and staging due to its similar lesion uptake rate with no increase in benign uptakes," the authors wrote.

"The findings from this study represent very important reassurance regarding the safety of testosterone as masculinizing treatment," says Joshua Safer, MD, FACP, FACE.

The research projects are assessing combination therapies in advanced prostate cancer that include the use of relugolix.

The phase 2a open-label dose ascending study to assess the safety, tolerability, and efficacy of VMB-100 in female patients with moderate SUI is expected to begin in the first half of 2024.

"Rather than receiving definitive radiation treatment for localized disease, these patients may have received treatment aimed at preventing the further spread of what was incorrectly identified as metastatic disease," says Thomas Hope, MD.

According to the survey, 79% of Black men know that genetic information can help improve prostate cancer outcomes, yet 33% indicated that they would be unwilling or uncertain to provide DNA samples, even if it meant finding new treatment options.

“These findings suggest that to reduce health disparities for Veterans in the prevention of prostate cancer, clinicians should consider an individual Veteran’s risk for prostate cancer including factors such as race and age," says Kyung Min Lee, PhD.

The ProstACT GLOBAL study is investigating second-line TLX591 in combination with the current standard of care (SOC) vs SOC alone in patients with mCRPC who have progressed on a novel androgen axis drug.

Notably, the study represents a 57% increase in the number of non-European participants compared with previous prostate cancer genome-wide association studies.

“This study confirms what many women who’ve struggled with persistent UTIs already know, which is that the current methods of diagnosing and treating these infections are inadequate," says Jennifer Rohn, PhD.

The CPT code will be effective beginning July 1, 2024.